{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T09:05:07Z","timestamp":1780650307279,"version":"3.54.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012217","name":"Xuzhou Medical University","doi-asserted-by":"publisher","award":["SHJDBF2024104"],"award-info":[{"award-number":["SHJDBF2024104"]}],"id":[{"id":"10.13039\/501100012217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012217","name":"Xuzhou Medical University","doi-asserted-by":"publisher","award":["XYFY2020038"],"award-info":[{"award-number":["XYFY2020038"]}],"id":[{"id":"10.13039\/501100012217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012217","name":"Xuzhou Medical University","doi-asserted-by":"publisher","award":["XYFC2020001"],"award-info":[{"award-number":["XYFC2020001"]}],"id":[{"id":"10.13039\/501100012217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010854","name":"Jiangsu Provincial Commission of Health and Family Planning","doi-asserted-by":"publisher","award":["H201628"],"award-info":[{"award-number":["H201628"]}],"id":[{"id":"10.13039\/501100010854","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010854","name":"Jiangsu Provincial Commission of Health and Family Planning","doi-asserted-by":"publisher","award":["2016103003"],"award-info":[{"award-number":["2016103003"]}],"id":[{"id":"10.13039\/501100010854","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000703"],"award-info":[{"award-number":["82000703"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270731"],"award-info":[{"award-number":["82270731"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470726"],"award-info":[{"award-number":["82470726"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20211054"],"award-info":[{"award-number":["BK20211054"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.xkme.2026.101354","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:17:20Z","timestamp":1775456240000},"page":"101354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent Advancements in the Therapeutic Landscape of IgA Nephropathy and the Impact of Dual Blockers: Telitacicept"],"prefix":"10.1016","volume":"8","author":[{"given":"Karthick Kumaran","family":"Munisamy Selvam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.xkme.2026.101354_bib1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.imbio.2009.10.003","article-title":"Emerging pathways of non-genomic glucocorticoid (GC) signalling in T cells","volume":"215","author":"Boldizsar","year":"2010","journal-title":"Immunobiology"},{"issue":"4","key":"10.1016\/j.xkme.2026.101354_bib2","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.xkme.2026.101354_bib3","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.xkme.2026.101354_bib4","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.ajkd.2007.03.013","article-title":"A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study","volume":"49","author":"Manno","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.xkme.2026.101354_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10238-019-00580-9","article-title":"Clinical and pathological features of immunoglobulin A nephropathy patients with nephrotic syndrome","volume":"19","author":"Han","year":"2019","journal-title":"Clin Exp Med"},{"issue":"3","key":"10.1016\/j.xkme.2026.101354_bib6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","article-title":"IgA nephropathy: core curriculum 2021","volume":"78","author":"Pattrapornpisut","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.xkme.2026.101354_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/7806438","article-title":"Galactose-deficient IgA1 as a candidate urinary polypeptide marker of IgA nephropathy?","volume":"2016","author":"Suzuki","year":"2016","journal-title":"Dis Markers"},{"issue":"3","key":"10.1016\/j.xkme.2026.101354_bib8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"49","key":"10.1016\/j.xkme.2026.101354_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat7117","article-title":"Gut T cell-independent IgA responses to commensal bacteria require engagement of the TACI receptor on B cells","volume":"5","author":"Grasset","year":"2020","journal-title":"Sci Immunol"},{"issue":"2","key":"10.1016\/j.xkme.2026.101354_bib10","first-page":"795","article-title":"BAFF is involved in the pathogenesis of IgA nephropathy by activating the TRAF6\/NF-\u03baB signaling pathway in glomerular mesangial cells","volume":"21","author":"Cao","year":"2020","journal-title":"Mol Med Rep"},{"issue":"1","key":"10.1016\/j.xkme.2026.101354_bib11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.kint.2019.01.031","article-title":"A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy","volume":"96","author":"Myette","year":"2019","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.xkme.2026.101354_bib12","article-title":"Pathogenic role of a proliferation-inducing ligand (APRIL) in murine IgA nephropathy","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.xkme.2026.101354_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109234","article-title":"Complement factor H variants are associated with microangiopathy lesions in IgA nephropathy","volume":"112","author":"Hou","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101354_bib14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.kint.2018.02.023","article-title":"Circulating complement factor H-related protein 5 levels contribute to development and progression of IgA nephropathy","volume":"94","author":"Zhu","year":"2018","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.xkme.2026.101354_bib15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/ndt\/gfz241","article-title":"Glomerular endothelial activation, C4d deposits and microangiopathy in immunoglobulin A nephropathy","volume":"36","author":"Trimarchi","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.xkme.2026.101354_bib16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrneph.2014.92","article-title":"Pathology of IgA nephropathy","volume":"10","author":"Roberts","year":"2014","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1016\/j.xkme.2026.101354_bib17","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1084\/jem.188.6.1185","article-title":"APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth","volume":"188","author":"Hahne","year":"1998","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.xkme.2026.101354_bib18","doi-asserted-by":"crossref","first-page":"R6","DOI":"10.1186\/ar1855","article-title":"B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels","volume":"8","author":"Collins","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.xkme.2026.101354_bib19","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3892\/mmr.2014.2359","article-title":"TLR9 and BAFF: their expression in patients with IgA nephropathy","volume":"10","author":"Li","year":"2014","journal-title":"Mol Med Rep"},{"issue":"4","key":"10.1016\/j.xkme.2026.101354_bib20","doi-asserted-by":"crossref","first-page":"683","DOI":"10.5301\/jn.5000218","article-title":"Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features","volume":"26","author":"Xin","year":"2013","journal-title":"J Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2026.101354_bib21","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.2016050496","article-title":"Toll-like receptor 9 stimulation induces aberrant expression of a proliferation-inducing ligand by tonsillar germinal center B cells in IgA Nephropathy","volume":"28","author":"Muto","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.xkme.2026.101354_bib22","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003099","article-title":"Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy","volume":"95","author":"Zhai","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.xkme.2026.101354_bib23","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/0961203315608254","article-title":"Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus","volume":"25","author":"Salazar-Camarena","year":"2016","journal-title":"Lupus"},{"issue":"13","key":"10.1016\/j.xkme.2026.101354_bib24","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1177\/0961203310375268","article-title":"Expressions of BAFF\/BAFF receptors and their correlation with disease activity in Chinese SLE patients","volume":"19","author":"Zhao","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.xkme.2026.101354_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cyto.2018.11.008","article-title":"BAFF-R and TACI expression on CD3+ T cells: interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus","volume":"114","author":"Salazar-Camarena","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.xkme.2026.101354_bib26","article-title":"Expression of BAFF, APRIL, and cognate receptor genes in lupus nephritis and potential use as urinary biomarkers","volume":"3","author":"Aguirre-Valencia","year":"2019","journal-title":"J Transl Autoimmun"},{"issue":"3","key":"10.1016\/j.xkme.2026.101354_bib27","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/cei.12894","article-title":"Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis","volume":"187","author":"Phatak","year":"2017","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"10.1016\/j.xkme.2026.101354_bib28","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/0961203313496302","article-title":"Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus","volume":"22","author":"Vincent","year":"2013","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.xkme.2026.101354_bib29","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/09612033221086123","article-title":"The relationship between serum A proliferation-inducing ligand and B-cell activating factor levels with disease activity and organ involvement in systemic lupus erythematosus","volume":"31","author":"Sari","year":"2022","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.xkme.2026.101354_bib30","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/art.23678","article-title":"Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus","volume":"58","author":"Petri","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.xkme.2026.101354_bib31","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/ard.2008.090928","article-title":"Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus","volume":"68","author":"Morel","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.xkme.2026.101354_bib32","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/ard.2004.022491","article-title":"Raised serum APRIL levels in patients with systemic lupus erythematosus","volume":"64","author":"Koyama","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.xkme.2026.101354_bib33","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.clim.2009.12.012","article-title":"Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices","volume":"135","author":"Hegazy","year":"2010","journal-title":"Clin Immunol"},{"issue":"6781","key":"10.1016\/j.xkme.2026.101354_bib34","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"issue":"5537","key":"10.1016\/j.xkme.2026.101354_bib35","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1126\/science.1061965","article-title":"BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF","volume":"293","author":"Thompson","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.xkme.2026.101354_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1169084","article-title":"Telitacicept for autoimmune nephropathy","volume":"14","author":"Cai","year":"2023","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.xkme.2026.101354_bib37","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.4049\/jimmunol.179.11.7276","article-title":"Regulated expression of BAFF-binding receptors during human B cell differentiation","volume":"179","author":"Darce","year":"2007","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.xkme.2026.101354_bib38","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/79802","article-title":"APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity","volume":"1","author":"Yu","year":"2000","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101354_bib39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.xkme.2026.101354_bib40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cellimm.2015.02.011","volume":"295","author":"Matsuda","year":"2015","journal-title":"Cell Immunol"},{"issue":"2","key":"10.1016\/j.xkme.2026.101354_bib41","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1074-7613(01)00183-2","article-title":"TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS","volume":"15","author":"Gross","year":"2001","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.xkme.2026.101354_bib42","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/14712598.2016.1169270","article-title":"Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser","volume":"16","author":"Scheinberg","year":"2016","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"10.1016\/j.xkme.2026.101354_bib43","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/cpdd.1316","article-title":"Safety, pharmacokinetics, and pharmacodynamics of subcutaneous sibeprenlimab in healthy participants","volume":"12","author":"Zhang","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"10.1016\/j.xkme.2026.101354_bib44","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/14712598.2023.2213800","article-title":"Emerging role of monoclonal antibodies in the treatment of IgA nephropathy","volume":"23","author":"Maixnerova","year":"2023","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.xkme.2026.101354_bib45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"10.1016\/j.xkme.2026.101354_bib46","doi-asserted-by":"crossref","first-page":"ii9","DOI":"10.1093\/ckj\/sfad200","article-title":"The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy","volume":"16","author":"Yeo","year":"2023","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.xkme.2026.101354_bib47","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.kint.2025.05.006","article-title":"Zigakibart demonstrates clinical safety and efficacy in a phase 1\/2 trial of healthy volunteers and patients with IgA nephropathy","volume":"108","author":"Kooienga","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.xkme.2026.101354_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105704","article-title":"Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS\/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis","volume":"159","author":"Yao","year":"2021","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"10.1016\/j.xkme.2026.101354_bib49","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.xkme.2026.101354_bib50","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.xkme.2026.101354_bib51","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1093\/rheumatology\/keab115","article-title":"Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus","volume":"60","author":"Wallace","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.xkme.2026.101354_bib52","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.xkme.2026.101354_bib53","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1681\/ASN.0000000541","article-title":"Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy","volume":"36","author":"Barratt","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101354_bib54","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/toxsci\/kfn105","article-title":"Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept","volume":"105","author":"Carbonatto","year":"2008","journal-title":"Toxicol Sci"},{"issue":"5","key":"10.1016\/j.xkme.2026.101354_bib55","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/rheumatology\/keq404","article-title":"Therapeutic effects of TACI-Ig on rats with adjuvant-induced arthritis via attenuating inflammatory responses","volume":"50","author":"Chang","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.xkme.2026.101354_bib56","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2249.2010.04293.x","article-title":"Therapeutic effects of TACI-Ig on rat with adjuvant arthritis","volume":"163","author":"Wang","year":"2011","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"10.1016\/j.xkme.2026.101354_bib57","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.intimp.2011.09.014","article-title":"TACI-Ig induces immune balance of Th cells in MLN via BLyS\/APRIL-receptors signaling in rats with adjuvant-induced arthritis","volume":"11","author":"Qin","year":"2011","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"10.1016\/j.xkme.2026.101354_bib58","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ejphar.2011.01.002","article-title":"Therapeutic effects of TACI-Ig on collagen-induced arthritis by regulating T and B lymphocytes function in DBA\/1 mice","volume":"654","author":"Liu","year":"2011","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101354_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000492237","article-title":"Efficacy and safety of telitacicept in IgA nephropathy: a retrospective, multicenter study","volume":"149","author":"Liu","year":"2025","journal-title":"Nephron"},{"issue":"1","key":"10.1016\/j.xkme.2026.101354_bib60","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2025.2449580","article-title":"Efficacy and safety of telitacicept in IgA nephropathy: a real-world study","volume":"47","author":"Dong","year":"2025","journal-title":"Ren Fail"},{"issue":"9","key":"10.1016\/j.xkme.2026.101354_bib61","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.ekir.2024.07.006","article-title":"Exploring novel adverse events of Nefecon","volume":"9","author":"Wang","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1016\/j.xkme.2026.101354_bib62","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf154","article-title":"Efficacy and safety of telitacicept in IgA nephropathy: real-world study outcomes","volume":"18","author":"Weng","year":"2025","journal-title":"Clin Kidney J"},{"issue":"9","key":"10.1016\/j.xkme.2026.101354_bib63","first-page":"694","article-title":"Les d\u00e9p\u00f4ts intercapillaires d'IgA-IgG [Intercapillary deposits of IgA-IgG]","volume":"74","author":"Berger","year":"1968","journal-title":"J Urol Nephrol (Paris)"},{"issue":"4 suppl","key":"10.1016\/j.xkme.2026.101354_bib64","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"issue":"23","key":"10.1016\/j.xkme.2026.101354_bib65","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.xkme.2026.101354_bib66","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1159\/000496000","article-title":"Efficacy and safety of agents in IgA nephropathy: an update network meta-analysis","volume":"43","author":"Yang","year":"2018","journal-title":"Kidney Blood Press Res"},{"issue":"2","key":"10.1016\/j.xkme.2026.101354_bib67","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/kisup.2012.23","article-title":"Chapter 10: Immunoglobulin A nephropathy","volume":"2","year":"2012","journal-title":"Kidney Int Suppl (2011)"},{"issue":"1","key":"10.1016\/j.xkme.2026.101354_bib68","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.xkme.2026.101354_bib69","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.kint.2021.04.002","article-title":"SGLT-2 inhibition in IgA nephropathy: the new standard of care?","volume":"100","author":"Barratt","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.xkme.2026.101354_bib70","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12882-023-03238-7","article-title":"Comparison between hydroxychloroquine and systemic corticosteroids in IgA nephropathy: a two-year follow-up study","volume":"24","author":"Si","year":"2023","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101354_bib71","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial","volume":"74","author":"Liu","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.xkme.2026.101354_bib72","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000487330","article-title":"Effects of hydroxychloroquine on proteinuria in immunoglobulin A nephropathy","volume":"47","author":"Yang","year":"2018","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101354_bib73","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial","volume":"15","author":"Pozzi","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101354_bib74","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1681\/ASN.2017060713","article-title":"Effects of two immunosuppressive treatment protocols for IgA nephropathy","volume":"29","author":"Rauen","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.xkme.2026.101354_bib75","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ndt\/gfg081","article-title":"Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide","volume":"18","author":"Tumlin","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.xkme.2026.101354_bib76","doi-asserted-by":"crossref","first-page":"c131","DOI":"10.1159\/000070232","article-title":"Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy","volume":"93","author":"Rasche","year":"2003","journal-title":"Nephron Clin Pract"},{"issue":"6","key":"10.1016\/j.xkme.2026.101354_bib77","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","article-title":"Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial","volume":"69","author":"Hou","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.xkme.2026.101354_bib78","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3760\/cma.j.issn.0366-6999.20132396","article-title":"Retrospective study of mycophenolate mofetil treatment in IgA nephropathy with proliferative pathological phenotype","volume":"127","author":"Liang","year":"2014","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"10.1016\/j.xkme.2026.101354_bib79","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1523-1755.2005.00460.x","article-title":"Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy","volume":"68","author":"Tang","year":"2005","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.xkme.2026.101354_bib80","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.xkme.2026.101354_bib81","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.xkme.2026.101354_bib82","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","article-title":"Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy","volume":"66","author":"Hogg","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"suppl 3","key":"10.1016\/j.xkme.2026.101354_bib83","article-title":"FC050: Nefecon\u00ae selectively modifies the composition of circulating immune complexes in IgA nephropathy","volume":"37","author":"Molyneux","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 3","key":"10.1016\/j.xkme.2026.101354_bib84","article-title":"P0344: Nefecon\u00ae (budesonide) selectively reduces circulating levels of BAFF (BLYS) and soluble BCMA and TACI in IgA nephropathy","volume":"35","author":"Molyneux","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"10084","key":"10.1016\/j.xkme.2026.101354_bib85","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstr\u00f6m","year":"2017","journal-title":"Lancet"},{"issue":"4 suppl","key":"10.1016\/j.xkme.2026.101354_bib86","article-title":"POS-830: Nefecon for the treatment of IgA nephropathy in patients at risk of progressing to end-stage renal disease: the NEFIGARD phase 3 trial results","volume":"6","author":"Barratt","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.xkme.2026.101354_bib87","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"issue":"10405","key":"10.1016\/j.xkme.2026.101354_bib88","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xkme.2026.101354_bib89","article-title":"Efficacy and safety of agents for IgA nephropathy: a network meta-analysis of randomized controlled trials","volume":"12","author":"Chen","year":"2025","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.xkme.2026.101354_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.xkme.2026.101354_bib91","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ekir.2023.01.041","article-title":"Targeting the alternative complement pathway with iptacopan to treat IgA nephropathy: design and rationale of the APPLAUSE-IgAN study","volume":"8","author":"Rizk","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"11","key":"10.1016\/j.xkme.2026.101354_bib92","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1016\/j.xkme.2026.101354_bib93","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.kint.2025.05.028","article-title":"Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy","volume":"108","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.xkme.2026.101354_bib94","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/nep.13592","article-title":"Is immunoglobulin A nephropathy different in different ethnic populations?","volume":"24","author":"Yeo","year":"2019","journal-title":"Nephrology (Carlton)"},{"issue":"5","key":"10.1016\/j.xkme.2026.101354_bib95","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/ki.2013.210","article-title":"Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease","volume":"84","author":"Barbour","year":"2013","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.xkme.2026.101354_bib96","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.xkme.2026.101354_bib97","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/ndt\/gfae173","article-title":"IgA class-switched CD27\u2212CD21+ B cells in IgA nephropathy","volume":"40","author":"Popova","year":"2025","journal-title":"Nephrol Dial Transplant"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526001159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526001159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:14:51Z","timestamp":1780647291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526001159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":97,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2590059526001159"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101354","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent Advancements in the Therapeutic Landscape of IgA Nephropathy and the Impact of Dual Blockers: Telitacicept","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101354","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101354"}}